Novartis to buy U.S. biotech in latest deal targeting firms in $1 billion to $3 billion range

Source: Market Watch | Published: September 9, 2025, 9:39 am | Read Original

Neutral 0.0

Novartis to buy U.S. biotech in latest deal targeting firms in $1 billion to $3 billion range

Novartis on Tuesday said it was buying a U.S. biotech working on a cardiovascular drug, continuing what’s been a flurry of acquisitions at a similar price point.

Read Source Login to use Pulse AI

Pulse AI Analysis

Pulse analysis not available yet. Click "Get Pulse" above.

This analysis was generated using Pulse AI, Glideslope's proprietary AI engine designed to interpret market sentiment and economic signals. Results are for informational purposes only and do not constitute financial advice.

More Like This

Glideslope AI

Novartis to buy U.S. biotech in latest deal targeting firms in $1 billion to $3 billion range

Novartis on Tuesday said it was buying a U.S. biotech working on a cardiovascular drug, continuing what’s been a flurry of acquisitions at a similar price point.

Market Watch • Sep 9, 2025 • Found on Glideslope.ai

Post hash: 98509528941754102516 • glideslope.ai/post/98509528941754102516

Sentiment

Neutral • Score: 0.0

-100 (Bearish) +100 (Bullish)

Fraywire Market Portal, Breaking Metrics Newsletter, and Glideslope AI are designed for informational purposes only. The content provided across these platforms—including, but not limited to, stock and crypto watchlists, price tracking, trade tracking, sentiment analysis, and news articles—should not be construed as financial advice or research reports. Users are encouraged to conduct their own research and consult with qualified financial professionals before making any investment decisions. While we strive to ensure the accuracy, completeness, and reliability of the information provided, Fraywire, Breaking Metrics, and Glideslope AI make no guarantees or warranties regarding the content's validity. By using these platforms, you acknowledge and agree that you are solely responsible for your own investment decisions and actions. Fraywire, Breaking Metrics, and Glideslope AI shall not be held liable for any losses or damages resulting from the use of the information provided.

Get Connected

Fraywire & Glideslope AI are Breaking Metrics productions.
Contact the developer for advertising opportunities, questions, and more at roy@rmahd.com

○ Subscribe
○ Fraywire+
○ Glideslope AI
○ Blog
○ RMAHD
○ Merch!

" selected code.

Pulse AI Analysis

Related Insights

More Like This

BlackRock CEO reveals central banks’ top question as gold dips below $4K

Toyota pledges $10B toward new auto plants in US: ‘Go out and buy a Toyota,’ Trump says

UBS lifts Amazon price target ahead of e-commerce giant’s earnings

The battle over DEI is messier than ever for companies

Mark Wahlberg buys a $37 million Florida mansion on ‘Billionaire’s Row’

European stocks turn negative as earnings, Fed decision hold spotlight; Novartis falls 3%